Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Old API Wind-down Ltd - Ordinary Shares ARLZQ

"Old API Wind-down Ltd, formerly Aralez Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in the acquisition, development, and commercialization of products primarily in cardiovascular, pain management and other specialty areas. Its key products include Fiorinal, Proferrin, Fibricor, Uracyst and Neovisc, Cambia and other marketed products. The company currently operates in two geographical markets, the United States and Canada. The firm generates most of its reven


OTCPK:ARLZQ - Post by User

Comment by snootchybootchyon Mar 18, 2017 3:52pm
146 Views
Post# 25997975

RE:RE:RE:CEO Purchased Half Million Shares!

RE:RE:RE:CEO Purchased Half Million Shares!kuatolives/goldendilemma, you fellas make good points but I'm really looking at Aralez in a different way.  My feeling is that the market has declared Yosprala a failure much too early.  There had been only five months of sales data since the drug was approved, and that duration spanned the Christmas/New Years holiday to boot.  Five months is much too early to start forecasting future Yosprala sales, especially when management has not had the opportunity yet to roll out their combination sales strategy with Zontivity.

At any rate, I would refer skeptics to the drug Entresto from Novartis.  Launch for the heart failure drug was also very slow but uptake is really starting to pick up steam now, about 20 months after it was approved.

I think the bottom is in.  Shorters can try to discount  Aralez to its cash level but clearly there is going to be support at the same levels insiders made their large purchases.
<< Previous
Bullboard Posts
Next >>